Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: William Marsh who wrote (97)	10/19/1999 7:06:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

William, I was overenthusiastic in my statement on how large the indication upgrade was. I falsely remembered the P1 HspE7 trial was for stage I CIN (mild dysplasia) but StressGen IR reminded me it is for CIN II and CIN III (moderate and severe dysplasia). Nonetheless, the Phase II will upgrade 2 levels from CIN III past "carcinoma in situ" into invasive cervical cancer. I regard the upgrade as positive since it indicates confidence in the therapy. I also asked IR about StressGen's costs on the AIN Phase II trial: Regarding the recent news release announcing that the NCI, through the AIDS Malignancy Consortium, would be supporting an investigator-led clinical trial of HspE7 in HIV+ patients with anal dysplasia: StressGen will not be paying for the trial costs but will be supplying quantities of HspE7 at no charge. Heat